Evan H. Zhang
YOU?
Author Swipe
View article: Data from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Data from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial Open
Purpose:Colorectal cancer is the second leading cause of cancer-related mortality in the United States. Chemotherapies based on 5-fluorouracil (5-FU), when combined with targeted agents, remain the standard of care for patients with metast…
View article: Supplementary Figure 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Supplementary Figure 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial Open
Supplementary Figure 1
View article: Supplementary Tables 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
Supplementary Tables 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial Open
Supplementary Tables
View article: supplementary materials 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial
supplementary materials 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial Open
supplementary materials
View article: Engineered protein circuits for cancer therapy
Engineered protein circuits for cancer therapy Open
Summary Many targeted therapies indirectly suppress cancer cells by inhibiting oncogenic signaling pathways such as Ras 1–4 . This renders them susceptible to resistance and limits their long-term clinical efficacy 4–10 . Engineered protei…
View article: Supplementary Figure 3 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 3 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 3 and legend
View article: Supplementary Figure 5 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 5 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 5 and legend
View article: Supplementary Methods from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Methods from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental methods
View article: Supplementary Figure 4 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 4 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 4 and legend
View article: Supplementary Figure 1 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 1 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 1 and legend
View article: Supplementary Figure 2 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplementary Figure 2 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Supplemental figure 2 and legend
View article: Data from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Data from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Colorectal cancer is the second leading cause of cancer mortality in the United States. Although immune checkpoint blockade therapies including anti-PD-1/PD-L1 have been successful in treating a subset of patients with colorectal cancer, t…
View article: Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer Open
Colorectal cancer is the second leading cause of cancer mortality in the United States. Although immune checkpoint blockade therapies including anti-PD-1/PD-L1 have been successful in treating a subset of patients with colorectal cancer, t…
View article: Supplemental Figure 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 2 shows the quantification of western blots shown in Figure 2A and 2B.
View article: Supplemental Figure 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 2 shows the quantification of western blots shown in Figure 2A and 2B.
View article: FIGURE 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Knockout of SIX4 reduces the efficacy of anti-PD-1 tumor suppression effect in vivo. A, Colony formation assays were performed in MC38 control and SIX4 knockout cells (gRNA2 and gRNA3) with representative images after MTT sta…
View article: Data from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Data from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
The cGAS/STING cytosolic DNA-sensing pathway plays a significant role in antitumor immunity. Expression of STING is tightly regulated and commonly reduced or defective in many types of cancer. We have identified SIX4 as a significant regul…
View article: Supplemental Figure 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 4 shows the quantification of western blots shown in Figure 2D.
View article: FIGURE 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
SIX4 modulates STING activation in colon cancer cells. A, MC38 SIX4 knockout cells and those with SIX4- or STING-reexpressing cells were treated with 10 µg/mL of DMXAA for 6 hours. Western blot analysis was performed to examine expr…
View article: Supplemental Figure 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 4 shows the quantification of western blots shown in Figure 2D.
View article: Supplemental Figure 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 1 shows the quantification of western blots shown in Figure 1A and 1B.
View article: FIGURE 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Knockout of SIX4 reduces the efficacy of anti-PD-1 tumor suppression effect in vivo. A, Colony formation assays were performed in MC38 control and SIX4 knockout cells (gRNA2 and gRNA3) with representative images after MTT sta…
View article: Supplemental Figure 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 1 shows the quantification of western blots shown in Figure 1A and 1B.
View article: Data from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Data from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
The cGAS/STING cytosolic DNA-sensing pathway plays a significant role in antitumor immunity. Expression of STING is tightly regulated and commonly reduced or defective in many types of cancer. We have identified SIX4 as a significant regul…
View article: FIGURE 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 1 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
SIX4 regulates expression of STING mRNA and protein. A, SIX4 expression was knocked out in MC38 cells by two gRNAs (gRNA2 and gRNA3). An empty vector (V) or SIX4-expressing vector (SIX4) was introduced into SIX4 knockout cells. Depl…
View article: Supplemental Figure 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 3 shows the quantification of western blots shown in Figure 2C.
View article: FIGURE 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 2 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
SIX4 modulates STING activation in colon cancer cells. A, MC38 SIX4 knockout cells and those with SIX4- or STING-reexpressing cells were treated with 10 µg/mL of DMXAA for 6 hours. Western blot analysis was performed to examine expr…
View article: FIGURE 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
SIX4 expression is positively associated with inflammatory response in colon cancer patient specimens. A, GSEA plots of enrichment in the Inflammatory Response signatures from MsigDB in colon cancer patient samples from TCGA stratif…
View article: FIGURE 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
FIGURE 4 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
SIX4 expression is positively associated with inflammatory response in colon cancer patient specimens. A, GSEA plots of enrichment in the Inflammatory Response signatures from MsigDB in colon cancer patient samples from TCGA stratif…
View article: Supplemental Figure 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression
Supplemental Figure 3 from SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression Open
Supplemental Figure 3 shows the quantification of western blots shown in Figure 2C.